Exenatide-Dapagliflozin Combo Enhances Kidney Protection: DECREASE Trial Dr Kartikeya Kohli24 May 2021 2:00 PMSodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are common hypoglycemic drugs. Previous...
Dapagliflozin may Improve Diabetic Retinopathy, Finds Study MD Bureau10 May 2021 1:00 PMDiabetic retinopathy (DR) is a leading cause of blindness and vision impairment. In a recent study presented at the Association for Research in Vision...
AstraZeneca Farxiga gets approval in US for CKD prevention Ruchika Sharma2 May 2021 4:00 AMUK: AstraZeneca's Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of...
FDA Approves dapagliflozin for treating Chronic Kidney Disease Dr Kartikeya Kohli1 May 2021 2:16 AMThe U.S. Food and Drug Administration has approved dapagliflozin oral tablets to reduce the risk of kidney function decline, kidney failure,...
SGLT2 inhibitor dapagliflozin significantly impacts urine metabolome in diabetics: Study Medha Baranwal18 April 2021 8:57 AMGreece: Dapagliflozin treatment is associated with a significant change in urine metabolome in patients with type 2 diabetes (T2D) independent of...
Dapagliflozin Reduces Blood Pressure by Vasodilation, Finds Study MD Bureau25 March 2021 2:28 PMHypertension and type 2 diabetes mellitus (T2DM) are risk factors for cardiovascular disease. Dapagliflozin improves both blood sugar and systolic...
Health Minister discusses side-effects of SGLT-2 inhibitors in the parliament Meghna A Singhania8 Feb 2021 10:40 AMNew Delhi: With the rising incidence of diabetes in the country, SGLT-2 inhibitors have emerged as one of the preferred modality of treatment....
Zydus Cadila net profit rises 41 percent to Rs 527 crore in Q3 Ruchika Sharma8 Feb 2021 4:30 AMAhmedabad: Pharmaceutical major Zydus Cadila said on Friday its profit after tax was up by 41 per cent to Rs 527 crore in Q3 FY21 as compared to the...
AstraZeneca gets CDSCO nod for Dapagliflozin in CKD MD Bureau17 Jan 2021 10:00 AMNew Delhi: The Subject Expert Committee (SEC), operative under the Central Drugs Standard Control Organization (CDSCO), has given its nod to...
Dapagliflozin going off-patent- NPPA brings Dapagliflozin, Metformin Combination under price control Farhat Nasim14 Jan 2021 11:45 AMNew Delhi: With the popular antidiabetic drug, Dapagliflozin going off-patent, the apex drug price regulator, National Pharmaceutical Pricing...
NPPA fixes retail price of 7 formulations, Details Ruchika Sharma9 Jan 2021 9:54 AMNew Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India...
AstraZeneca gets USFDA Priority Review for Farxiga to treat chronic kidney disease Ruchika Sharma7 Jan 2021 6:30 AMCKD, a condition defined by decreased kidney function, is often associated with a heightened risk of heart disease or stroke, or the need for dialysis...
